Lifestyle
- Quit smoking
- Limit alcohol consumption
- Regular exercise
Homocysteine · Hcy · tHcy
Homocysteine levels in the blood, reflecting methionine metabolism and B vitamin status.
Ranges may vary slightly by lab; fasting recommended for accurate measurement.
Homocysteine (Hcy) is a sulfur-containing amino acid that is an intermediate in the metabolism of methionine and cysteine. It is primarily measured in its total plasma form, which includes free and protein-bound homocysteine. Researchers have found that elevated levels of homocysteine are associated with a wide range of conditions, most notably cardiovascular diseases and neurological disorders. Elevated homocysteine levels have been linked to an increased risk of atherosclerosis, stroke, and cognitive impairments, among other conditions. In the context of athletic performance and biohacking, maintaining optimal homocysteine levels is considered important for cardiovascular health and cognitive function, which are crucial for longevity and peak performance. However, several factors can influence homocysteine levels, including vitamin B deficiencies, genetic factors, and lifestyle choices such as smoking and alcohol consumption. It is important to consider these confounders when interpreting test results, and fasting is generally recommended before testing to ensure accuracy.
Klinische Bedeutung
Elevated homocysteine levels are clinically significant as they are associated with an increased risk of cardiovascular diseases, stroke, and cognitive impairments. Lower levels are generally considered non-problematic but may indicate adequate B vitamin status.
Progressively rising homocysteine levels suggest increasing cardiovascular risk. Retest in 3 months if elevated.
Falling levels may indicate improved B vitamin status or lifestyle changes.
Re-test Interval
3 months if outside optimal range
Note:
Consult a healthcare provider before starting any supplementation, especially if you have underlying health conditions.
Draw blood at the same time of day for consistency, as levels may fluctuate.
Testing Frequency
Annually for adults at risk of cardiovascular diseases.
May affect
Current research suggests that reference ranges for homocysteine levels and optimal targets for intervention remain debated, particularly regarding values above 10 μmol/L. Researchers have not yet established the full impact of confounding factors, such as vitamin B12 status and genetic predispositions, on homocysteine levels. Additionally, clinical questions remain unanswered about the long-term effects of lowering homocysteine on cognitive impairment and cardiovascular outcomes in diverse populations.
755
Total Citations
2
Human/RCT
4.1
Avg. Influence
2025
Latest
This review discussed the relationship between cysteine and homocysteine as biomarkers for various diseases. Researchers found that elevated homocysteine levels are toxic and associated with conditions such as cardiovascular diseases, diabetes, and certain cancers. The study suggests that monitoring these biomarkers can aid in disease prevention and diagnosis.
Researchers reviewed over 100 diseases linked to high levels of homocysteine, particularly cardiovascular and central nervous system conditions. They found that lowering homocysteine levels through B vitamin treatment could potentially prevent several diseases, including neural tube defects and cognitive impairment in the elderly. The study suggests that a homocysteine level of 10 μmol/L or below is likely safe, while levels above 11 μmol/L may require intervention.
Researchers conducted a systematic review and meta-analysis to evaluate blood biomarkers for post-stroke cognitive impairment. They found that homocysteine levels were significantly higher in patients with cognitive impairment following a stroke compared to those without. This suggests that homocysteine could serve as a potential biomarker for assessing cognitive impairment after a stroke.
This study reviewed the role of homocysteine (Hcy) as a pathological biomarker for bone disease. Researchers found that elevated Hcy levels could contribute to osteoporosis and bone loss through oxidative stress, highlighting the need for further investigation into its effects on bone health.
Researchers assessed the significance of elevated homocysteine (Hcy) levels in Parkinson's disease (PD) patients with dementia. The study found that Hcy levels were higher in PD patients with dementia compared to those without, indicating a potential link to cognitive decline.
Researchers performed a meta-analysis to investigate the correlation between serum homocysteine levels and cerebral infarction (CI). They found that CI patients had significantly higher serum homocysteine levels compared to healthy controls, indicating a strong association. The study suggests that monitoring homocysteine levels could be important for early diagnosis and treatment assessment of CI.
Researchers characterized clinical subtypes of Parkinson's disease (PD) and found significant differences in serum homocysteine (Hcy) levels among the identified subtypes. The study suggests that Hcy could be a useful biomarker for stratifying PD severity.
Researchers explored the role of hyperhomocysteinemia as a risk factor for atherosclerosis and cardiovascular diseases. They identified that high homocysteine levels can lead to the production of atherogenic biomolecules, contributing to disease development. The study emphasizes that treatment with B vitamins can lower homocysteine levels and potentially reduce cardiovascular risks.
This study examined the biomarkers used to evaluate vitamin B12 status, including total plasma homocysteine. Researchers found that there is no single 'gold standard' test for B12 deficiency, leading to diagnostic uncertainty. They suggest that using a combination of biomarkers may improve the detection of B12 deficiency.
This study investigated the relationship between blood homocysteine (Hcy) and phosphorylated tau-217 (p-tau217) levels in Alzheimer's disease. Researchers found that increased Hcy levels were associated with cognitive impairment and cortical thinning, suggesting Hcy as a modifiable risk factor for disease progression.
Research publications about Homocystein over time
10totalLog lab results, track trends and optimize your biomarkers over time.
This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer